

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/173721 A1

(51) International Patent Classification:

A61K 31/404 (2006.01) A61P 35/00 (2006.01)
C07D 209/30 (2006.01)

(21) International Application Number:

PCT/US2021/019477

(22) International Filing Date:

24 February 2021 (24.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/981,520 25 February 2020 (25.02.2020) US

(71) Applicant: **UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION** [US/US]; UT Conference Center, Suite 211, 600 Henley Street, Knoxville, Tennessee 37996 (US).

(72) Inventors: **NARAYANAN, Ramesh**; 5426 Courtney Avenue, Tuscaloosa, Alabama 35406 (US). **PONNUSAMY,**

Thamarai; 141 Gajeongro Yuseong-gu, Daejeon 34114 (KR). **MILLER, Duane D.**; 1646 Forsythe Trail, Collierville, Tennessee 38017 (US). **HE, Yali**; 2072 Duntreath Meadows, Germantown, Tennessee 38139 (US). **HWANG, Dong-Jin**; 5162 Jon Oak Drive, Arlington, Tennessee 38002 (US).

(74) Agent: **COHEN, Mark S.** et al.; Pearl Cohen Zedek Latzer Baratz LLP, 7 Times Square, 19th Floor, New York, New York 10036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF




Figure 15

(57) Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*